These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37755671)

  • 1. Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.
    Neveu D; Mallett Moore T; Zambrano B; Chen A; Kürzinger ML; Marcelon L; Singh Dhingra M
    Infect Dis Ther; 2023 Oct; 12(10):2367-2386. PubMed ID: 37755671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
    Díez-Domingo J; Simkó R; Icardi G; Chong CP; Zocchetti C; Syrkina O; Bchir S; Bertrand-Gerentes I
    Infect Dis Ther; 2024 Aug; 13(8):1835-1859. PubMed ID: 38955966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
    Knuf M; Rämet M; Breinholt Stærke N; Bertrand-Gerentes I; Thollot Y; B'Chir S; Arroum H; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052657. PubMed ID: 35445641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
    Chang LJ; Hedrick J; Christensen S; Pan J; Jordanov E; Dhingra MS
    Vaccine; 2020 Apr; 38(19):3560-3569. PubMed ID: 32209248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
    Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS
    Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)
    van der Vliet D; Vesikari T; Sandner B; Martinón-Torres F; Muzsay G; Forsten A; Adelt T; Diaz Gonzalez C; Simko R; B'Chir S; Neveu D; Jordanov E; Dhingra MS
    Epidemiol Infect; 2021 Feb; 149():e50. PubMed ID: 33541457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
    Áñez G; Hedrick J; Simon MW; Christensen S; Jeanfreau R; Yau E; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1292-1298. PubMed ID: 32209015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
    Matsuoka O; Ujiie M; Kikuchi H; Otake S; Chansinghakul D; Inoue T; Varghese K; Sirisuphmitr N; Hashiguchi T; Zambrano B; Nakama T; Frago C; Jordanov E; Dhingra MS
    Jpn J Infect Dis; 2023 May; 76(3):174-182. PubMed ID: 36724939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study.
    Robertson CA; Jacqmein J; Selmani A; Galarza K; Oster P
    Hum Vaccin Immunother; 2023 Dec; 19(1):2160600. PubMed ID: 36632042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study.
    Dhingra MS; Peterson J; Hedrick J; Pan J; Neveu D; Jordanov E
    Vaccine; 2020 Jul; 38(33):5194-5201. PubMed ID: 32565344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.
    Vesikari T; Borrow R; Forsten A; Findlow H; Dhingra MS; Jordanov E
    Hum Vaccin Immunother; 2020 Jun; 16(6):1306-1312. PubMed ID: 32233959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
    Piazza FM; Virta M; Paassilta M; Ukkonen B; Ahonen A; Esteves-Jaramillo A; Forsten A; Seppa I; Ding J; Neveu D; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-10. PubMed ID: 34085900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.
    Kirstein J; Pina M; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1299-1305. PubMed ID: 32233961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
    Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
    Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.
    Esteves-Jaramillo A; Koehler T; Jeanfreau R; Neveu D; Jordanov E; Singh Dhingra M
    Vaccine; 2020 Jun; 38(28):4405-4411. PubMed ID: 32387012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion.
    Ricci S; Azzari C; Amodio E; Castiglia P
    Expert Rev Vaccines; 2023; 22(1):447-456. PubMed ID: 37144288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
    Martinón-Torres F; Bertrand-Gerentes I; Oster P
    Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study.
    Cornish MJ; Hedrick JA; Gabrielsen AA; Johnson AD; Miriam Pina L; Rehm C; Pan J; Neveu D; Da Costa X; Jordanov E; Dhingra MS
    Vaccine; 2022 Mar; 40(10):1421-1438. PubMed ID: 35144847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
    Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
    Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.
    Deeks ED
    BioDrugs; 2010 Oct; 24(5):287-97. PubMed ID: 20795751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.